Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D
- 1 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 45 (1) , 28-33
- https://doi.org/10.1097/qai.0b013e3180385aa0
Abstract
To determine whether there are differences in coreceptor use in subjects infected with HIV-1 envelope subtypes A and D that could explain the differences in progression rates between these subtypes in a rural Ugandan cohort. HIV-1 was subtyped in env by V3 sequencing or heteroduplex mobility assay. Coreceptor use was determined by the ability of the isolates to replicate in U87 CD4 cells expressing different coreceptors. The Fisher exact test was used to examine the relation between coreceptor use and subtype, clinical stage, and V3 charge. The Kruskall-Wallis nonparametric test was used to examine the association between median CD4 cell counts, coreceptor use, and subtype. Logistic regression was used to examine predicted coreceptor use at different CD4 groupings. Isolates from 66 participants were analyzed. Thirty-one were infected with subtype A, and 35 were infected with subtype D. Although this work was based on a small sample size, we found statistically significant differences. The probability of having an X4 virus was higher in subtype D infections than in subtype A infections among those with a non-AIDS clinical status (Fisher exact test, P = 0.040). Logistic regression analysis, in which we predicted X4 use by subtype and stratified by CD4 group, confirmed these findings among those with a CD4 count >200 cells/microL (likelihood ratio test, P = 0.003). R5 viruses were associated with higher median CD4 cell counts than X4 or X4/R5 (Kruskall-Wallis test, P = 0.0045). A V3 charge of +5 and greater was highly associated with X4 virus (Fisher exact test, P = 0.006). These subtype differences in coreceptor use may partially explain the faster progression rates we have previously reported in individuals infected with subtype D compared with subtype A. Our observations may have implications for the future use of coreceptor inhibitors in this population.Keywords
This publication has 43 references indexed in Scilit:
- Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV‐1 InfectionThe Journal of Infectious Diseases, 2005
- Among 46 Near Full Length HIV Type 1 Genome Sequences from Rakai District, Uganda, Subtype D and AD Recombinants PredominateAIDS Research and Human Retroviruses, 2002
- Effect of Human Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease Progression in a Large Cohort of HIV‐1–Positive Persons in UgandaThe Journal of Infectious Diseases, 2002
- Coreceptor Change Appears after Immune Deficiency Is Established in Children Infected with Different HIV-1 SubtypesAIDS Research and Human Retroviruses, 2002
- Predominance of HIV-1 Subtype A and D Infections in UgandaEmerging Infectious Diseases, 2000
- Partial Resistance to Infection by R5X4 Primary HIV Type 1 Isolates in an Exposed-Uninfected Individual Homozygous for CCR5 32-Base Pair DeletionAIDS Research and Human Retroviruses, 1999
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected IndividualsThe Journal of Experimental Medicine, 1997
- Syncytium-Inducing and Non-Syncytium-Inducing Capacity of Human Immunodeficiency Virus Type 1 Subtypes Other Than B: Phenotypic and Genotypic CharacteristicsAIDS Research and Human Retroviruses, 1994
- The Impact of the Syncytium-Inducing Phenotype of Human Immunodeficiency Virus on Disease ProgressionThe Journal of Infectious Diseases, 1994